Methods for providing personalized medicine test ex vivo for hematological neoplasms
First Claim
1. A method for analyzing cellular responsiveness to drugs, comprising:
- obtaining a sample of a tissue from a hematological neoplasm that has been withdrawn from a patient;
dividing the sample of tissue into at least 35 aliquots;
combining the at least 35 aliquots each having a drug composition; and
measuring apoptosis in at least one cell population in each of the at least 35 aliquots.
2 Assignments
0 Petitions
Accused Products
Abstract
Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.
105 Citations
55 Claims
-
1. A method for analyzing cellular responsiveness to drugs, comprising:
-
obtaining a sample of a tissue from a hematological neoplasm that has been withdrawn from a patient; dividing the sample of tissue into at least 35 aliquots; combining the at least 35 aliquots each having a drug composition; and measuring apoptosis in at least one cell population in each of the at least 35 aliquots. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
-
24. A method for analyzing the response of neoplastic cells to drugs, comprising:
-
obtaining a sample of tissue from a hematological neoplasm that has been collected from a patient; separating the sample of tissue into at least 35 aliquots; combining at least 35 of the aliquots with a drug composition, wherein the drug composition in each aliquot differs from the drug composition in all other aliquots by at least one of drug identity, concentration, or a combination thereof, and wherein the drug compositions collectively include at least one non-cytotoxic drug; incubating the aliquots that are combined with a drug composition; and for each incubated aliquot, analyzing responsiveness of at least one type of neoplastic cell to the drug composition. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
39. A method for facilitating treatment of a hematological neoplasm in a patient, comprising:
-
providing a tissue sample that has been obtained from the patient that includes neoplastic cells; incubating each of at least 6 portions of the sample with a different drug or drug combination; analyzing each said portion of the sample to ascertain a degree of apoptosis of neoplastic cells in that portion; and generating a printed or electronic report of results from the analysis step indicating at least the portion, drug, or drug combination having the greatest degree of apoptosis. - View Dependent Claims (40, 41)
-
-
42. A device for analyzing the response of neoplastic cells to potential drug regimens, comprising:
-
a plurality of chambers; and a different drug or drug combination in each of the plurality of chambers, wherein the chambers collectively comprise; at least one chamber comprising a plurality of drugs; at least one chamber comprising a cytotoxic drug; and a total of at least 10 different drugs in the collective chambers. - View Dependent Claims (43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
-
-
55. A composition for the treatment of chronic lymphoid leukemia (CLL), comprising fludarabine or a pharmaceutically acceptable salt thereof and sertraline or a pharmaceutically acceptable salt thereof.
Specification